Physicochemical and functional assessment of messenger RNA 5′Cap-end impurities under forced degradation conditions

The 5'Cap is a modified nucleotide structure added to the 5'end of mRNA, which plays a critical role in stability and translation of the molecule. Accurate characterization of 5'Cap impurities is crucial during development of mRNA therapeutics. Here, we utilized orthogonal liquid chromatography-mass spectrometry (LC-MS) workflows to characterize Cap-1-modified mRNA. A complex mixture of uncapped and, notably, 5'Cap chemical degradation variants, was detected. We subjected Cap-1 analogs to process-related forced degradation conditions and characterized multiple degradation routes of the 5'Cap structure, including hydrolysis and depurination. 5'Cap hydrolysis was observed in a representative <i>in vitro</i> transcription (IVT) reaction buffer and was driven by factors including pH, temperature, and the presence of spermidine and MgCl<sub>2</sub>. Method-induced artifactual degradation occurred during LC-MS data acquisition, emphasizing the importance of using reference standards and optimizing methods to reduce such artifacts. We investigated the effect of 5'Cap degradation on expression and reactogenicity <i>in vitro</i> using model mRNAs with elevated impurity levels. mRNA 5'Cap degradation impurities significantly impacted protein expression but did not trigger innate immune response pathways. 5'Cap degradation impurities should be considered as a critical quality attribute of mRNA therapeutics and should be monitored during production, purification, formulation, and storage.

Authors

Institutions

Publication Details

Journal
Molecular Therapy — Nucleic Acids
Published
2025-05-20
DOI
https://doi.org/10.1016/j.omtn.2025.102570
Citations
2
Primary Topic
RNA Interference and Gene Delivery
Type
article
Field-Weighted Citation Impact
1.61

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Physicochemical and functional assessment of messenger RNA 5′Cap-end impurities under forced degradation conditions

Tracy Nissan, Ruma Rani, Stefano Leone, Eivor Örnskov et al.
2 citations
Molecular Therapy — Nucleic Acids
RNA Interference and Gene Delivery
1.61
article

Physicochemical and functional assessment of messenger RNA 5′Cap-end impurities under forced degradation conditions

Tracy Nissan, Ruma Rani, Stefano Leone, Eivor Örnskov, J A Button, Stephanie M. Bates, Diamantis C. Sideris, Sara Maria David Trabulo, Fritz Schweikart, Nicholas J. Bond, George Thom, Aditya Murthy, James C. Hutchinson, Chandra Shekhar Lal, R. D. Shannon
article en
2 citations

Abstract

The 5'Cap is a modified nucleotide structure added to the 5'end of mRNA, which plays a critical role in stability and translation of the molecule. Accurate characterization of 5'Cap impurities is crucial during development of mRNA therapeutics. Here, we utilized orthogonal liquid chromatography-mass spectrometry (LC-MS) workflows to characterize Cap-1-modified mRNA. A complex mixture of uncapped and, notably, 5'Cap chemical degradation variants, was detected. We subjected Cap-1 analogs to process-related forced degradation conditions and characterized multiple degradation routes of the 5'Cap structure, including hydrolysis and depurination. 5'Cap hydrolysis was observed in a representative <i>in vitro</i> transcription (IVT) reaction buffer and was driven by factors including pH, temperature, and the presence of spermidine and MgCl<sub>2</sub>. Method-induced artifactual degradation occurred during LC-MS data acquisition, emphasizing the importance of using reference standards and optimizing methods to reduce such artifacts. We investigated the effect of 5'Cap degradation on expression and reactogenicity <i>in vitro</i> using model mRNAs with elevated impurity levels. mRNA 5'Cap degradation impurities significantly impacted protein expression but did not trigger innate immune response pathways. 5'Cap degradation impurities should be considered as a critical quality attribute of mRNA therapeutics and should be monitored during production, purification, formulation, and storage.

Molecular Therapy — Nucleic AcidsVol. 36(2)
AstraZeneca (South Korea) (KR), AstraZeneca (Australia) (AU), AstraZeneca (Italy) (IT), AstraZeneca (Spain) (ES)
AstraZeneca
Zero hunger
Openalex Percentile: Top 17%
RNA Interference and Gene Delivery
1.61
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.